Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8380851 | 0.91 | TYMP (0.43) | TYMPADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL30657731 | 0.90 | TYMP (0.49) | TYMPADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4304539 | 0.90 | TYMP (0.49) | TYMPADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL6513979 | 0.88 | TYMP (0.47) | TYMPADORA2AADORA2BADORA1P2RY12 | |
| SCHEMBL31260592 | 0.85 | ADORA3 (0.55) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL19493363 | 0.84 | TYMP (0.67) | TYMPADORA1P2RY12 | |
| SCHEMBL29679722 | 0.84 | TYMP (0.67) | TYMPADORA1P2RY12 | |
| SCHEMBL8386141 | 0.84 | TYMP (0.67) | TYMPADORA1P2RY12 | |
| SCHEMBL17304362 | 0.84 | TYMP (0.67) | TYMPADORA1P2RY12 | |
| SCHEMBL917678 | 0.84 | TYMP (0.67) | TYMPADORA1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050074771-A1 | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6803198-B2 | COMPOUND FOR USE IN HUMAN THERAPEUTICS AND DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20030039977-A1 | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. | 2003-02-27 | — | — | US | disclosed |
| US-6322987-B1 | FOR TREATING AN ANIMAL HAVING A DISEASE CHARACTERIZED BY UNDESIRED PRODUCTION OF PROTEIN | ISIS PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074771-A1 | Carbamate-derivatized nucleosides and oligonucleosides | RNGTT, NUDT21, DUT | TYMP 6/4885ADORA3 449/4885ADORA2A 986/4885 |
| US-20030039977-A1 | Carbamate-derivatized nucleosides and oligonucleosides | RNGTT, NUDT21, DUT | TYMP 6/4885ADORA3 449/4885ADORA2A 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.